Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrEcISE: PGx-guided Escitalopram for Pediatric Anxiety
NCT04623099Phase 4Recruiting
- Sponsor
- University of Cincinnati
- Start
- Mar 2021
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of escitalopram in generalized anxiety disorder (GAD), Social Anxiety Disorder (SAD), separation anxiety disorder (SAD), sponsored by University of Cincinnati. Started Mar 2021; status: recruiting.
02
Drugs
escitalopram
03
Conditions
generalized anxiety disorder (GAD)Social Anxiety Disorder (SAD)separation anxiety disorder (SAD)
Beyond the preview
Go deeper on NCT04623099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04623099.